SurroMed Inc.

One constant refrain from the late September rEvolution 2005 Symposium for Chief Scientific Officers on Kiawah Island—other than the knotty issue of research productivity—was the increasing importan

VCs won't go near traditional diagnostics. But some are starting to bet on biomarkers that expedite drug R&D and commercialization. Only one problem: they've yet to come up with the right business mod

Encouraged by lessons learned from the 1990s genomics implosion and pharma's urgent need to re-invent the R&D process, some venture capitalists see renewed, albeit narrow opportunity in tool companies

Accepted in discovery, they are paving the way for biomarker development and eventually, molecular diagnostics VCs and entrepreneurs first became interested in microarray technologies for genomic appl